GlassScriptPhysician profile
Benigno B Bobon
NPI 1487645032
$21,607.37
in general payments reported to CMS, 2019-2025
64 companies · $2,584 in 2025
The $2,584 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,419 · 2020: $2,257 · 2021: $3,757 · 2022: $4,529 · 2023: $2,480 · 2024: $2,582 · 2025: $2,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,586 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,585.80 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,892.76 | 2019-2025 | Evenity, Repatha, Repatha |
| Novo Nordisk INC | $2,791.72 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $2,436.85 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $1,540.18 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,330.26 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $899.33 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $823.14 | 2019-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $693.61 | 2019-2023 | |
| Eisai INC. | $558.94 | 2019-2021 | |
| Esperion Therapeutics, INC. | $548.70 | 2020-2025 | Nexletol, Nexlizet |
| Biohaven Pharmaceutical Holding Company LTD. | $548.40 | 2022 | |
| Ibsa Pharma INC. | $470.65 | 2020-2024 | Tirosint, Licart |
| Amarin Pharma, INC. | $410.64 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $398.65 | 2019-2024 | Xarelto |
| Allergan, INC. | $347.77 | 2019-2021 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benigno Bobon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.